CVE:KNE Kane Biotech (KNE) Stock Price, News & Analysis C$0.02 -0.01 (-20.00%) As of 03:40 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartInsider TradesNews and Trends About Kane Biotech Stock (CVE:KNE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kane Biotech alerts:Sign Up Key Stats Today's RangeC$0.02▼C$0.0350-Day RangeC$0.02▼C$0.0352-Week RangeC$0.02▼C$0.05Volume132,200 shsAverage Volume171,648 shsMarket CapitalizationC$4.10 millionP/E RatioN/ADividend Yield3.08%Price TargetN/AConsensus RatingN/A Company Overview Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada. Read More Receive KNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kane Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KNE Stock News HeadlinesKane Biotech Reaches Distribution Agreement For Revyve ProductsSeptember 3, 2026 | finance.yahoo.comKane Biotech Expands Canadian Commercial Reach with Ontario Medical Supply Inc.September 2, 2026 | financialpost.comFHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 8 at 1:00 AM | Stansberry Research (Ad)Kane Biotech Inc.: Kane Biotech Announces Second Quarter 2026 Financial ResultsAugust 28, 2026 | finanznachrichten.deKane Biotech Q2 Net Loss Expands; Revenue DeclinesAugust 28, 2026 | rttnews.comKane Biotech Announces Second Quarter 2026 Financial ResultsAugust 27, 2026 | financialpost.comFKane Biotech’s revyve® Research Presented at Military Health System Research SymposiumAugust 25, 2026 | financialpost.comFKane Biotech Announces Engagement of DNA AdvisorsAugust 5, 2026 | financialpost.comFSee More Headlines KNE Stock Analysis - Frequently Asked Questions How have KNE shares performed this year? Kane Biotech's stock was trading at C$0.04 at the beginning of 2026. Since then, KNE stock has decreased by 50.0% and is now trading at C$0.02. How do I buy shares of Kane Biotech? Shares of KNE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Kane Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kane Biotech investors own include Mason Resources (LLG), Datametrex AI (DM) and Allstar Health Brands (ALST). Industry, Sector and Symbol Stock ExchangeCVE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolCVE:KNE CIKN/A Webwww.kanebiotech.com Phone+1-204-4531301FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$6.03 million Net Margins-6,980.20% Pretax MarginN/A Return on Equity273.53% Return on Assets-58.43% Debt Debt-to-Equity Ratio-197.52 Current Ratio0.61 Quick Ratio0.39 Sales & Book Value Annual SalesC$38.72 thousand Price / Sales105.92 Cash FlowC$0.00 per share Price / Cash Flow8.50 Book ValueC$0.00 per share Price / Book-4.13Miscellaneous Outstanding Shares205,057,000Free FloatN/AMarket CapC$4.10 million OptionableNot Optionable Beta1.08 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (CVE:KNE) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our PartnersThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredMusk just exposed the crack in his empireSpaceX's IPO raised approximately $85.7 billion in gross proceeds. Days later, the company revealed its combin...The Oxford Club | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThe Closest Thing to a Virtual AI Monopoly Wall Street Is IgnoringA little-known company may be building the closest thing to a virtual AI monopoly that Wall Street has yet to ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kane Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kane Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
